Tag - AMRX

SVB Leerink cuts Amneal Pharma to MP; PT to $3 from $4

SVB Leerink downgraded Amneal Pharmaceuticals (NYSE:AMRX) to “market perform” from “outperform” and lowered its price target to $3 from $4 after the company cut its guidance. The stock closed at $2.76 on Nov. 6. Analyst...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.